{"id":"hip1601","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL2146140","moleculeType":"Small molecule","molecularWeight":"848.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HIP1601 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. Its extended half-life enables once-weekly or less frequent dosing.","oneSentence":"HIP1601 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:44:00.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04325620","phase":"PHASE3","title":"Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-06-10","conditions":"Non-erosive Gastroesphageal Reflux Disease","enrollment":208},{"nctId":"NCT04204629","phase":"PHASE1","title":"Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-01-13","conditions":"Healthy Volunteer","enrollment":25},{"nctId":"NCT04080726","phase":"PHASE3","title":"Efficacy and Safety of HIP1601 Capsule","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-25","conditions":"Erosive Gastroesophageal Reflux Disease","enrollment":213},{"nctId":"NCT03882112","phase":"PHASE1","title":"Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-04-17","conditions":"Heathy Volunteer","enrollment":24},{"nctId":"NCT03372850","phase":"PHASE1","title":"Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations","status":"UNKNOWN","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-02-15","conditions":"Healthy","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["esomeprazole","Esomeprazole (40 mg or 20 mg)"],"phase":"phase_3","status":"active","brandName":"HIP1601","genericName":"HIP1601","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HIP1601 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}